Activated macrophages can release macrophage extracellular traps (METs), extracellular web-like structures that contribute to tissue injury during sepsis. In a lipopolysaccharide (LPS)-induced sepsis model, MET levels were reported to be markedly increased in both the liver and the circulation. The immunometabolite itaconate, produced by the enzyme aconitate decarboxylase 1 (encoded by Irg1/Acod1), emerged from the study as an important endogenous suppressor of MET formation and a modulatory factor in sepsis-associated liver pathology.
Genetic ablation of immune responsive gene 1 (Irg1), the gene responsible for synthesizing itaconate in activated macrophages, led to increased MET release in the LPS sepsis model. Loss of Irg1 was associated with worsened hepatic injury and reduced survival in septic mice, indicating that endogenous itaconate production provides protection against LPS-mediated liver damage. Specific experimental details such as animal numbers, LPS dosing, time points, or quantitative outcome measures were not reported in the provided abstract.
The study assessed the effects of an itaconate derivative, 4-octyl itaconate (4-OI), which was found to robustly suppress MET formation in the LPS model. Treatment with 4-OI also ameliorated liver injury in this sepsis context. The abstract reports a clear protective effect of exogenous itaconate analog administration, but it does not provide specifics on dosing regimens, routes of administration, timing relative to LPS challenge, or quantitative measures of liver injury in the summary provided.
Mechanistic investigation identified activation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) as a key action of 4-OI. Activation of Nrf2 led to intracellular antioxidant responses that lowered reactive oxygen species (ROS) levels in macrophages. The abstract indicates that this Nrf2-driven ROS scavenging is central to the downstream suppression of MET formation by 4-OI.
The study connects ROS to activation of peptidylarginine deiminase 4 (PAD4), an enzyme that catalyzes histone citrullination, a post-translational modification critical for chromatin decondensation and extracellular trap release. By reducing intracellular ROS through Nrf2 activation, 4-OI prevented ROS-dependent PAD4 activation, thereby inhibiting histone citrullination and the subsequent release of METs. This identifies a mechanistic chain: 4-OI → Nrf2 activation → reduced ROS → decreased PAD4 activation → reduced histone citrullination → suppressed MET release.
Importantly, the suppression of MET formation by 4-OI was Nrf2-dependent; absence of Nrf2 abolished the inhibitory effect of 4-OI on METs according to the abstract. This finding positions the Nrf2–ROS–PAD4 axis as a central regulatory pathway controlling MET formation in LPS-induced sepsis and supports the concept that targeting metabolic regulators of antioxidant transcriptional programs can modulate detrimental innate immune responses in sepsis.
The authors propose that the itaconate–Nrf2 axis reveals a metabolic–immune pathway by which itaconate reduces sepsis-associated liver injury through suppression of METs, suggesting a potential therapeutic approach. The abstract does not report clinical data; all experiments described were preclinical. Animal experiments were approved by the Animal Care and Use Committee of Tongji Medical College of Huazhong University of Science and Technology. The authors declared no known competing financial interests. Specific experimental parameters (for example, sample sizes, statistical outcomes, or detailed protocols) are not provided in the abstract and would require consultation of the full text for comprehensive assessment.
This study links a macrophage-derived metabolite, itaconate, to inhibition of MET-mediated tissue damage in an LPS sepsis model via activation of Nrf2 and downstream suppression of ROS–PAD4 signaling. The findings support further investigation of itaconate derivatives such as 4-OI as modulators of innate immune-driven organ injury in sepsis, and they highlight Nrf2 and PAD4 as mechanistic targets for limiting extracellular trap–related pathology. Detailed methodological and quantitative results were not included in the abstract and should be reviewed in the full article for translational planning and experimental replication.